Apoptosis: Targets in Pancreatic Cancer
Sabine Westphal and Holger Kalthoff*

Address: Molecular Oncology, Clinic for General and Thoracic Surgery, University of Kiel, Arnold-Heller-Str. 7, 24105 Kiel, Germany
Email: Sabine Westphal - sabinewe@yahoo.de; Holger Kalthoff* - hkalthoff@email.uni-kiel.de
* Corresponding author

Abstract
Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease.

Review
Pancreatic cancer is one of the most malignant tumors with a very poor prognosis. Although pancreatic cancer has an incidence of about 10 cases/100,000 persons it is still the fourth male and fifth female leading cause of cancer-related death in the Western world [1]. Most of the newly diagnosed patients present with an already unresectable tumor stage. The 5-year survival rate of patients with pancreatic cancer receiving surgery and chemotherapy ranges from 1%–2% [2]. One of the reasons for this low survival rate is the insensitivity of pancreatic cancer to most oncologic therapies like chemotherapy, radiotherapy and immunotherapy [3–10]. Tumor development and progression as well as resistance to most oncologic therapies result mainly from lacking response to apoptotic stimuli.

Apoptosis or programmed cell death is a central regulator of tissue homeostasis [reviewed in [11]]. Multicellular organisms eliminate redundant, damaged or infected cells by apoptosis. Because chemotherapy and radiotherapy act primarily by inducing apoptosis, defects in the apoptotic pathway can cause cancer cell resistance [12,13]. Tumor cells utilize multiple pathways to down-modulate apoptosis [14].

Apopotosis mediated by death receptors belonging to the tumor-necrosis factor (TNF) receptor superfamily is the best-studied pathway in cells (Figure 1) [15,16]. Members of the TNF receptor family, TNF, Fas (Apo-1, CD95) and TRAIL (TNF-related apoptosis-inducing ligand)-R [16] share a common internal domain, the so-called death domain [17]. These receptors are activated by their natural ligands TNFα, FasL, and TRAIL, respectively. The interaction between receptor and ligand causes trimerization of receptor followed by recruitment of FADD (Fas-associated death domain protein) and procaspase-8 to the death domain forming the DISC (death-inducing signaling complex) [18]. At the DISC, cleavage of procaspase-8 yields the active form of this protease [18]. In type I cells, the amount of activated caspase-8 is sufficient to initiate apoptosis via direct activation of the central effector caspase,
Apoptosis mediated by death receptors of the TNF family in type I and type II cells. Apoptosis can be initiated by two alternative pathways: in type I cells the amount of initiator caspases is sufficient to induce executioner caspases directly or in type II cells the enhancing effect of mitochondria is necessary. Active executioner caspases cleave the death substrates, which results in apoptosis.
caspase-3. In type II cells, the signal enhancing-effect of mitochondria is needed to induce apoptosis [19]. The Bcl-2 family member BID mediates activation of mitochondria in response to death receptor activation. BID is cleaved by active caspase-8 producing tBID, which is translocated to the mitochondria [19]. tBID becomes integrated into the mitochondria membrane and induces release of cytochrome c and other apoptogenic factors from the intermembranous space of mitochondria [20,21]. In the cytoplasm, cytochrome c forms a complex with Apaf-1 (apoptotic protease activating factor-1), ATP and procaspase-9 termed the apoptosome. Like caspase-8, caspase-9 can be considered an initiator caspase, which is activated by cleavage at the apoptosome and activates in turn executioner caspases, mainly caspase-3, -6 and -7 [22]. Cleavage of death substrates, DNA fragmentation, and cleavage of cytoskeletal proteins finally lead to cell death [22].

This complex pathway is controlled and influenced by a variety of different pro- and anti-apoptotic factors. The balance of these effectors is important to ensure tissue homeostasis. Activation or downregulation of pro- and anti-apoptotic genes influence cancer cell viability, cancer cell sensitivity to chemotherapy and radiotherapy, and tumor development and progression (Figure 2).

This review will focus on the knowledge about deregulation of apoptotic proteins and pathways in pancreatic cancer and possible therapeutic approaches based on these findings.

**Death receptors**
As described above, apoptosis is mediated mainly by members of the TNF death receptor superfamily proteins including Fas (Apo-1, CD95) and TRAIL-R and their natural ligands. Deregulation of these pathways may contribute to abnormal tumor growth [23,24].

The Fas-FasL system is believed to represent one of the main apoptotic cell death-signaling pathway [25]. Fas or FasL over- and under-expression has been shown in a variety of human carcinomas including lung [26], renal [27] and colon cancer [28]. Findings concerning Fas receptor expression in pancreatic carcinomas are contradictorily. It has been demonstrated recently that Fas mRNA was increased in pancreatic carcinomas [29]. Contrarily, an in vivo study revealed that both membranous Fas and cytoplasmic Fas receptors could not be detected invasive ductal-type pancreatic adenocarcinomas [30]. Together, these data suggest that tumor cells can evade apoptosis by downregulation of the Fas receptor.

In contrast to FasL, TRAIL is not toxic to normal cells [31]. Unlike other tumor cells, TRAIL receptors are highly expressed at the surface of pancreatic carcinoma cells [32]. Additionally, it has been demonstrated that repeated treatment of different pancreatic cell lines with TRAIL caused sustained and profound cell death [33]. These results show that the TRAIL system in principal is functional in pancreatic cancer but is blocked at some stage downstream in the apoptotic pathway among which is the expression of non-functional receptors, so-called decoy receptors. Approaches to initiate apoptosis by application of TRAIL to cancer cells were successful in mammary carcinomas, intracranial gliomas and colon carcinomas [34]. However, the fact that under certain conditions this therapy induces apoptosis also in normal healthy hepatocytes causing hepatic necrosis [35] dampened the optimistic expectations.

**FAP-1**
FAP-1 (Fas-associated phosphatase-1) is a non-receptor protein tyrosine phosphatase. It has been demonstrated that FAP-1 can block the function of Fas by interaction with its carboxy-terminal three amino acids [10,36,37]. Cell lines resistant to Fas-mediated apoptosis strongly overexpressed FAP-1 and it also was highly expressed in tumor cells in pancreatic carcinoma tissues [37]. In contrast, Capan-1, a pancreatic cancer cell line highly sensitive to Fas-mediated apoptosis, totally lacks FAP-1 expression [37]. Stable transfection of Capan-1 cells with a FAP-1 cDNA strongly decreases the sensitivity to Fas-mediated apoptosis [37]. Inhibition of Golgi anterograde transport by Brefeldin A suggested that FAP-1 could prevent translocation of Fas from intracellular stores to the cell surface [37] resulting in insufficient receptor density at the cell surface. Modulation of FAP-1 expression or suppression of its enzymatic activity may be the basis of a novel therapy for pancreatic cancer.

**The role of mitochondria**
In type II cells, the apoptosis-enhancing effect of mitochondria is necessary to induce the full apoptotic phenotype. It has been demonstrated that pancreatic cancer cell lines are type II cells [19,32,38]. The Bcl-2 family members play the major role in this pathway.

**Bcl-2 family**
At the center of the cell’s decision to live or to die in response to an apoptotic signal is the Bcl-2 family of apoptotic regulators [39]. The Bcl-2 family is the best-characterized group of apoptosis-mediating factors and can be divided into two main groups according to their functional properties; anti-apoptotic proteins like Bcl-x<sub>L</sub> and Bcl-2 and pro-apoptotic proteins, such as Bax, Bak and Bad. Bcl-2 proteins interact with other molecules through an α-helical domain termed BH-3 domain. This interaction is believed to be important for regulation of apoptosis [40].
Figure 2
Influences of pro-and anti-apoptotic effectors on death receptor-mediated apoptosis. Apoptosis is controlled by several pro-(green) and anti-(red) apoptotic proteins. The balance of these proteins are important to ensure tissue homeostasis.
Bcl-2 is located at the cytoplasmic face of the mitochondrial outer membrane, at the ER-membrane and the nuclear envelope and may register damage of these compartments and affect their behavior [41]. Bcl-2 directly or indirectly prevents the release of cytochrome c from mitochondria in a variety of tissues [41]. High expression of Bcl-2 is found in various human tumors [42]. Interestingly, it has been shown that Bcl-2 expression is normal or even decreased in pancreatic cancer cells [43,44]. Preclinical animal and clinical phase II studies using Bcl-2 antisense constructs, such as G3139, in combination with different chemotherapeutics show significant regression of different cancers [45,46]. However, it is uncertain if this therapeutic approach will be successful in pancreatic cancer showing normal or decreased Bcl-2 expression levels.

Bcl-x exists in two distinct isoforms in humans. Bcl-xL, the longer form, functions in an anti-apoptotic manner. Bcl-xS, the shorter form, in contrast, functions as an apoptosis promoter. Like Bcl-2, Bcl-xL also prevents cytochrome c release from mitochondria [reviewed in [47]]. Different studies showed that most likely every cell type is protected from mitochondrial outer membrane, at the ER-membrane and the nucleus [47]. However, it is uncertain if this therapeutic approach will be successful in pancreatic cancer showing normal or decreased Bcl-2 expression levels.

Bax is a pro-apoptotic member of the Bcl-2 family that resides in the cytosol and translocates to mitochondria upon induction of apoptosis [52]. It has been demonstrated that ectopically expressed Bax in human embryonic kidney cells (293T cells) induced cytochrome c release and caspase activation [53]. However, overexpression of Bax did not influence the apoptosis rate or expression of Bcl-2 and Bcl-xL in human pancreatic cancer cells transduced with a retroviral expression vector [54]. But Bax significantly increased the sensitivity to chemotherapeutic drugs like gemcitabine and 5-Fu when transduced to pancreatic cancer cell line ASPC-1 cells [54]. Although Bax failed to substantially increase susceptibility of the pancreatic cell line Colo357 towards gemcitabine in vitro, in vivo data from a SCID mouse model suggest that pancreatic tumors overexpressing Bax caused higher sensitivity to gemcitabine and therefore stronger tumor regression [B. Schniewind, unpublished data]. That indicates that overexpression of Bax may have therapeutic application in enhancing the efficacy of chemotherapy in pancreatic cancer. A recent study revealed that a binary adenoviral vector system (Ad/GT-Bax + Ad/hTERT-GV16) using the human telomerase reverse transcriptase (hTERT) promoter to induce Bax gene expression was able to induce apoptosis in pancreatic cancer cell lines [55]. Transduced cells not only showed Bax overexpression but also an increased level of caspase-3. Another study revealed that increased levels of Bax and reduced expression of Bcl-2 are involved in the growth-inhibitory effect of cisplatin in pancreatic cancer cells. [56].

Another member of pro-apoptotic proteins of Bcl-2 family is Bak. In pancreatic cancer, Bak expression and apoptosis occur in regions of chronic inflammation surrounding the cancer cells but not in the tumor cells themselves [57]. This may facilitate tumor growth and spread. Recent studies have demonstrated that Bak, a typical pro-apoptotic protein of Bcl-2 family, binds with its BH3 domain to both Bcl-2 and Bcl-xL but mediates its pro-apoptotic functions through inhibition of Bcl-xL, but not Bcl-2 [58]. To restore the function of downregulated pro-apoptotic Bcl-2 family members, there are many efforts to develop peptides and non-peptide agents that mimic the function of these proteins [59].

The key enzymes for arachidonic acid metabolism, lipoxigenases (LOXs) and cyclooxygenases (COXs) influence the development and progression of several human cancers including pancreatic cancer [60]. It has been shown that both COXs and LOXs are upregulated in human pancreatic cancer tissues. Inhibitor studies revealed that blocking these enzymes inhibit pancreatic cancer growth and induce apoptosis. Further investigations pointed out that blockade of LOXs induce apoptosis through...
cytochrome c release, caspase-9 activation and changes in the levels of Bcl-2 family proteins [61].

In summary, the deregulation of Bcl-2 family both the pro- and the anti-apoptotic proteins play a crucial role in development, growth and expansion of pancreatic cancer. Several approaches based on these findings have been demonstrated to be a tool potentially influencing pancreatic cancer also in a clinical setting.

Caspases and caspase inhibitors

Caspases

The central component of apoptosis is a proteolytic system involving a family of cysteine proteases termed caspases. All caspases are expressed as proenzymes. Activation involves proteolytic processing [62]. Caspases initiate and execute cell death by inactivating anti-apoptotic proteins, shutting down DNA replication and repair [63], reorganization of the cytoskeleton [64] and disruption of the nuclear lamina [65].

Caspases are highly regulated by a variety of different inhibitors and activators. The induced proximity or oligomerization model explains that caspases exist as inactive monomers. The effectors of caspases bring the caspases in close proximity, allowing for their intermolecular autoproteolytic activation [66]. For example, activation of procaspase-8 requires association with its cofactor FADD (Fas-associated protein with death domain) [67] and procaspase-9 must interact with APAF-1 to become functional [68].

Important caspase-8 inhibitors represent the FADD-like ICE inhibitory proteins (FLIPs) [69]. Two forms, FLIP_L (long form) and FLIP_S (short form) have been characterized [70]. FLIP_L is a structural homologue of caspase-8 but it lacks amino acid residues that are critical for caspase activity [70–72]. FLIP_L competes with procaspase-8 for binding to FADD at the DISC, thus preventing caspase activation [66]. Very interestingly, it has been shown that FLIP_L is overexpressed both in pancreatic cancer cell lines resistant to Fas mediated apoptosis and pancreatic tumors [73]. This may promote progression of malignant pancreatic tumors.

Recent studies suggest that FLIP is not simply an inhibitor of death-receptor-induced apoptosis but it is involved in activation of NF-κB by recruiting adaptor proteins like TRAF [74]. NF-κB is known to regulate several genes that mediate tumorigenesis and metastasis [reviewed in [75]]. This may also contribute to tumor growth. Downregulation of FLIP in prostate cancer cell line resulted in sensitization to Fas-mediated apoptosis [76]. Recently, it has been demonstrated that natural and synthetic ligands of the transcription factor PPARγ (peroxysome proliferator-

activated receptor γ) sensitize tumor cells to apoptosis by decreasing the level of FLIP [77]. Equivalent data concerning pancreatic cancer are eagerly awaited. It has been shown that caspase expression is more or less normal in pancreatic carcinoma. In contrast, effectors blocking caspase activation or function like FLIPs are deregulated in pancreatic cancer leading to resistance to death receptor mediated apoptosis.

A new therapeutic approach uses somatostatin receptor subtype 2 (sst2) to activate caspase-3 and therefore to induce apoptosis in pancreatic cancer [78]. Likewise, sst2 treatment of human cancer cell lines with Diospyrin, a bifunctional agent, resulted in induction of apoptosis mediated via activation of caspase-3 and caspase-8 [79].

Irofulven (MGI 114, 6-hydroxymethylacylfulvene) induces apoptosis via caspase activation in pancreatic carcinoma cells [80].

IAP family

The inhibitor of apoptosis (IAP) family including cIAPs, XIAP and survivin can block apoptosis through interaction with members of the caspase family. IAPs are characterized by a domain termed the baculoviral IAP repeat (BIR) necessary for caspase interaction [81,82]. At least one BIR domain is necessary for suppression of apoptosis [83]. Another structural feature of IAPs is the presence of a carboxy terminal RING finger domain [83]. But it seems that this domain is not always strictly required for inhibition of apoptosis [84–87]. Overexpression of XIAP, cIAP1, cIAP2 and survivin has been demonstrated to suppress apoptosis [reviewed in [83]]. The cellular function of the IAP family members cIAP1, cIAP2 and XIAP is largely unclear. These proteins seem to be involved in pathogenesis of small-cell lung cancer [88], non-small cell lung cancer [89], myeloid leukemia cells [90] and prostate cancer [91]. Concerning pancreatic cancer, there are only few data on the involvement of cIAP1, cIAP2 and XIAP in the pathogenesis of this type of cancer. Our own results indicate increased levels of cIAP1, cIAP2 and XIAP in pancreatic cancer cell lines highly resistant to Fas- and TRAIL-induced apoptosis (A. Trauzold, unpublished data). Therefore, changes of expression of cIAP1, cIAP2 and XIAP may also have a role in the pathogenesis also in pancreatic cancer.

Survivin

Survivin has been identified as a new member of the inhibitor of apoptosis (IAP) family. Survivin is characterized by a unique structure that discriminates it from all other members of the IAP family. It contains only a single BIR domain and lacks a carboxy terminal RING finger domain. Survivin is expressed in the G2/M phase of the cell cycle in
a cycle-regulated manner [92]. It directly binds to and inhibits both caspase-3 and caspase-7 activity leading to arrest of apoptosis [93].

Survivin expression is not detectable in differentiated normal adult cells of any organ [94] but it is highly expressed in a wide range of cancer tissues [95] including neuroblastoma [96], colorectal [97] and stomach [98] carcinoma. It has been demonstrated recently that survivin is also frequently expressed in malignant pancreatic ductal tumors [99]. Because survivin is a potent caspase-inhibitor, its overexpression in cancer cells is implicated in the resistance to different apoptotic stimuli including chemotherapy. Molecular manipulation of survivin expression may enhance chemotherapy and radiation therapy not only in pancreatic cancer.

**SMAC/DIABLO**

IAPs are inhibited by a protein named SMAC/DIABLO (Second mitochondria-derived activator of caspase/direct IAP binding protein with low pi) [100,101]. SMAC/DIABLO is synthesized as a precursor protein and is imported into mitochondria [100]. Upon cellular stress, SMAC/DIABLO is released into the cytosol. In the cytosol it promotes cell death by preventing IAP inhibition of caspasases [102]. Like cytochrome c, release of SMAC/DIABLO from the mitochondria is inhibitable by Bcl-2 [100]. SMAC/DIABLO could have a therapeutic application in enhancing the effect of chemotherapeutics by binding IAPs that are overexpressed in a variety of carcinoma cells including pancreatic cancer. Recently it has been shown that SMAC/DIABLO fusion peptide was able to enhance apoptosis induced by diverse anticancer agents including paclitaxel, etoposide and others in MCF-7 breast cancer cells [103].

**Growth Factors**

Growth factor independence is a hallmark of tumors and is known to give cells a selective growth advantage [104]. Mutations of tumor suppressor genes and oncogenes lead to a loss of regulation in the expression and/or activation of both growth factors and their receptors [105]. Human pancreatic cancer cells are reported to produce multiple growth factors including insulin-like growth factor (IGF) and the receptors IGF-1 receptor (IGF-1R) and IGF-2 receptor, epidermal growth factor (EGF), EGF receptor (EGFR) and ErbB2, transforming growth factor-α (TGF-α), and transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), vascular endothelial growth factors (VEGF) and their receptors [106–115].

**Insulin-like growth factor (IGF)**

Insulin-like growth factors (IGFs), including IGF-1 and IGF-2, are mitogenic peptides involved in the regulation of cell proliferation, differentiation and apoptosis [116,117]. Exogenous IGF-1 increased cell proliferation and activated MAPK and AKT signaling pathways in pancreatic cell lines [118,119]. IGF-2 might function in the switch from the quiescent to the proliferative state [120]. In multiple myeloma cells IGF-1 stimulates sustained activation of NF-κB and AKT and upregulates a series of anti-apoptotic proteins including FLIP, survivin, cIAP-2 and XIAP [121].

IGF-1R shows the highest binding affinity for IGF-1, although IGF-2 can also bind and activate the receptor [117]. IGF-1R as well as IGF-1 and IGF-2 have been found to be upregulated in pancreatic cancer [122]. This leads to down-modulation of apoptosis and survival of cancer cells through the PI3K/AKT pathway.

**Epidermal growth factor (EGF)**

Epidermal growth factor (EGF) stimulates proliferation and differentiation in a wide range of cell types through its corresponding receptor, EGFR. The EGFR gene is overexpressed in the majority of pancreatic ductal adenocarcinomas and human pancreatic cancer cell lines [123]. EGFR binds EGF and TGF-α with high affinity, and both ligands are overexpressed in pancreatic cancer [123]. Additionally, the overexpression of both the EGF receptor and its ligand in human pancreatic cancer is associated with enhanced tumor aggressiveness and shorter survival following tumor resection [124].

Treatment of pancreatic cancer cell lines with Erbitux (IMC-C225) anti-EGFR antibody in combination with gemcitabine and radiation resulted in complete regression or growth inhibition of cancer cells in a preclinical setting [125]. This combinatory treatment shows potential clinical application in the treatment of pancreatic cancer in humans.

**Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)**

Vascular endothelial growth factor (VEGF) is a potent and specific angiogenic factor. VEGF is known to be a key player for tumor growth [126,127]. Fibroblast growth factors (FGFs) are mitogenic polypeptides that signal via FGF receptors (FGFRs). Both certain FGFs and VEGF and their receptors are overexpressed in pancreatic cancer cells [111,112]. A soluble receptor for VEGF (sVEGF) functions as a dominant-negative inhibitor of receptor suppresses tumor angiogenesis and enhances apoptosis of cancer cells [128]. This effect was increased by combined use of sVEGF and a soluble FGF receptor (sFGFR1) in lung and pancreatic cancer cell lines [129].

**Transforming growth factor alpha (TGF-α)**

TGF-α is structurally and functionally related to members of the EGF family [130]. Numerous human solid tumors express high levels of TGF-α [131]. Recent work has
shown that overexpression of TGF-α in liver has a dramatic protective effect on Fas-mediated apoptosis in TGF-α transformed mice. Mice with TGF-α overexpression in the pancreas develop ductal pancreatic cancer [132]. Interestingly, expression of Bcl-xL, an anti-apoptotic protein, was greatly increased in these transgenic mice and may partic-

Figure 3
Effects causing pancreatic cancer and possible therapeutic approaches. Multiple changes of apoptotic proteins contribute to pancreatic cancer development and progression. But many therapeutic approaches are developed to restore normal sensitivity to apoptotic stimuli and therefore to repress pancreatic cancer.
ipate in protective role of TGF-\(\alpha\) [133]. This may contribute to apoptosis resistance in pancreatic cancer cells.

**Transforming growth factor beta (TGF-\(\beta\))**

TGF-\(\beta\) is a multifunctional cytokine regulating a broad spectrum of cellular activity including cell-cycle control, differentiation, and apoptosis [reviewed in 134]. TGF-\(\beta\) is a factor mediating growth inhibition and induction of apoptosis [134,135]. TGF-\(\beta\) is involved in many events of apoptotic pathways. It cooperates with Fas [136] and TGF-\(\alpha\) [137], down-regulates the anti-apoptotic proteins Bcl-x\(_L\) and Bcl-2 and activates caspase-1, -3, -8 and -9 [138,139]. Another mechanism of TGF-\(\beta\)-induced apoptosis has been proposed following the finding that TGF-\(\beta\) down-regulates NF-\(\kappa\)B activity by the induction of the expression of I\(\kappa\)B \(\alpha\), a specific inhibitor of NF-\(\kappa\)B [140]. TGF-\(\beta\) initiates its cellular response by activation of specific downstream intracellular effectors termed SMAD proteins [reviewed in 141]. Escape from TGF-\(\beta\)/SMAD-induced apoptosis is frequently observed in tumors. Mutations and changes of expression levels of TGF-\(\beta\) and SMAD proteins could be observed also in pancreatic cancer tissues [142,143]. For example, SMAD 4, a tumor suppressor in the TGF-\(\beta\) signaling pathway is genetically inactivated in about 55% of all pancreatic adenocarcinomas. Patients with pancreatic adenocarcinomas with SMAD4 expression live significantly longer [144].

**Other factors and signaling pathways**

**Nuclear factor of \(\kappa\)B (NF-\(\kappa\)B)**

Nuclear factor \(\kappa\)B (NF\(\kappa\)B) is a sequence-specific transcription factor that is involved in many cellular activities including the inflammatory and immune response. NF-\(\kappa\)B also inhibits apoptosis by activation of several anti-apoptotic proteins [145], reviewed in [146] like cIAPs, FLIPs and the Bcl-2 family member Bcl-x\(_L\) [147]. Normally, NF-\(\kappa\)B remains as a heterodimeric complex consisting of p50, p65, and is kept by I\(\kappa\)B \(\alpha\) in an inactive state in the cytoplasm. A variety of stimuli like cytokines, pathogens, carcinogens or stress can lead to degradation of I\(\kappa\)B \(\alpha\) and p50–p65 heterodimer is translocated to the nucleus, binds the DNA at the promoter region and activates anti-apoptotic genes [148]. It has been demonstrated recently that NF-\(\kappa\)B contributes to apoptosis resistance in different cancers including pancreatic cancer [38,148]. This suggests that NF-\(\kappa\)B is an ideal target for chemotherapeutic therapies of cancer. Inhibition of NF-\(\kappa\)B by Gliotoxin, MG132 or Sulphasalazine [149] sensitizes pancreatic cancer cells to apoptosis induced by etoposide (VP16) or doxorubicin. Furthermore, inhibition of NF-\(\kappa\)B by food-derived polyphenols like quercetin decreased pancreatic cancer growth and prevented metastasis [150]. Quercetin decreased primary tumor growth, increased apoptosis by mitochondrial depolarization, cytochrome c release, caspase 3 activation, and inhibition of NF-\(\kappa\)B activation.

**PK\(\mu\)**

Protein kinases control and modulate a variety of cellular activities. Members of the protein kinase C (PKC) family have been shown to be involved in cell proliferation and differentiation [151]. Screening of expression pattern of PKC isoforms pointed out that the expression of PKC\(\mu\) correlates with the resistance to Fas-mediated apoptosis in different pancreatic cancer cell lines [40]. Cell lines highly resistant to Fas-mediated apoptosis show high PKC\(\mu\) expression levels [40]. It has been demonstrated that PKC\(\mu\) regulates apoptosis in several cancer cells including pancreatic carcinoma cells [152,153]. Overexpression of PKC\(\mu\) reduces the sensitivity of the cells to apoptosis induced by TNF [153]. This effect correlates with an enhanced expression of anti-apoptotic proteins like cIAP2, TRAF1, cFLIP and survivin as well as increased expression level of NF-\(\kappa\)B dependent genes [152–154].

**Survival signaling through PI3K/AKT**

Survival signals like growth factors, cytokines and hormones activate phosphatidylinositol 3-kinase (PI3K) [155]. Subsequently, PI3K activates AKT/PKB [156] that interferes with the apoptotic machinery. Activated AKT/PKB mediate cell survival via the regulation of numerous apoptotic relevant proteins such as the Bcl-2 family members BAD and Bcl-x\(_L\) and the transcription factor NF-\(\kappa\)B [157,158]. Survival signaling by AKT is counteracted by PTEN that antagonizes the action of PI3K. PI3K and AKT are overexpressed in a variety of cancers [159,160]. In addition, PTEN is frequently deleted in advanced tumors [161,162]. These alterations lead to a ‘constitutively active’ survival-signaling pathway that enhances the insensitivity of tumor cells to apoptosis induction. Additionally, EGFR directly influences PI3K [163]. Because PI3K mediates survival signals, EGFR overexpression leads to a decrease in the apoptotic response and therefore a stronger survival of cancer cells. Recent work has shown that the IGF-1R suppresses apoptosis by signaling through PI3K and AKT [120]. Activated AKT in turn phosphorylates the intracellular transducer, Bad, which modulates the activity of the apoptosis suppressors Bcl-2 and Bcl-x\(_L\) [164]. Additionally, AKT can directly phosphorylate caspase-9, which leads to inactivation of caspase-9 [165]. Strategies are pursued that aim to block the enzymatic activity of PI3K and PKB/AKT, in order to prevent inactivation of pro-apoptotic Bad. Wortmannin was shown to be a potent inhibitor of PI3K [160]. In several cancers including non-small-cell lung cancer [160] and pancreatic cancer [166], treatment of cells with wortmannin leads to inhibition of proliferation and increased apoptosis. Additionally, wortmannin enhanced gemcitabine-induced apoptosis in human pancreatic cells in vitro [167] and in vivo [168]. In contrast, studies investigating different pancreatic cancer cell lines pointed out that the PI3K/AKT pathway is not involved in gemcitabine-resistance [A. Arlt, unpublished data]. Nei-
ther did the basal AKT-activity correlate with the sensitivity towards gemcitabine treatment, nor did the inhibition of PI3K/AKT alter gemcitabine-induced apoptosis.

**p53**

The p53 pathway represents the molecular connection between the cell cycle and apoptosis. The p53 gene encodes a 53-kDa nuclear phosphoprotein. p53 inhibits cell growth through activation of cell cycle arrest and apoptosis [169]. The p53 gene is mutated in over 50% of human cancers. Pancreatic cell lines showed mutations in p53 at frequencies of 95% [170]. This enhances tumor development and progression. Currently, many therapeutic approaches were attempted to normalize p53 function in a variety of cancers including pancreatic cancer. Transfer of wild-type p53 induces apoptosis and produces significant growth suppression of pancreatic cancer in vitro and in vivo [170–172].

**Conclusion**

In the past, many efforts were made to cure patients from pancreatic cancer. Changes of expression and mutations of apoptotic proteins are common in pancreatic cancer cells and contribute to tumor development and progression. Consequently, pancreatic cancer has developed multiple resistance mechanisms to apoptosis. Many efforts to restore apoptosis and thereby reducing tumor growth were made with considerable success at least under preclinical conditions (Figure 3). Future therapies have to translate this knowledge into the clinic. They need to combine various therapeutic strategies and have to modulate selectively the sensitivity of pancreatic cancer cells to apoptosis without affecting normal cells.

**Authors’ contribution**

SW conducted literature review and wrote this article. HK supported this work by critical reading the manuscript and supervised the final editing. All authors read and approved the final manuscript.

**Acknowledgments**

This work was supported by grants of DFG (SBF 415/A 3) and IZKF/C 6. We thank A. Trauzold and H. Ungefroren for carefully reading this manuscript.

**References**

1. Parker SL, Tong T, Bolden S and Wingo PA Cancer statistics. *CA Cancer J Clin* 1997, 47:5-27
2. Coppola D Molecular prognostic markers in pancreatic cancer. *Cancer Contr 2000*, 7:421-427
3. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS and Eberlein TJ Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-I/CD95) receptors and aberrant expression of functional Fas ligand. *Surgery** 1999, 125:73-84
4. Beger HG, Büchler MW and Friess H Surgical results and indications for adjuvant measures in pancreatic cancer. *Chirurg** 1994, 65:246-252
5. Guo X, Friess H, Graber HU, Kashigaw M, Zimmermann A, Koc M and Büchler MW KAII expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. *Cancer Res* 1996, 56:4876-4880
6. Friess H, Büchler M, Kruger M and Beger HG Treatment of duct carcinoma of the pancreas with the LH-RH-analogue buserelin. *Pancreas* 1992, 7:516-521
7. Fodren-Sandberg A, Bickman PL and Andersson R Results of adjuvant therapy in resected pancreatic cancer. *Int J Pancreatol* 1997, 21:31-38
8. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC and Leonard RC Chemotherapy prolongs survival in inoperable pancreatic carcinoma. *Br J Surg* 1994, 81:882-885
9. von Bernstorf W, Voss M, Freichel S, Schmid A, Vogel I, Jahnk C, Hennen-Bruns D, Kremser B and Kalthoff H Systemic and local immunosuppression in pancreatic cancer patients. *Clin Cancer Res* 2001, 7:9252-932
10. Ungefroren H, Voss M, Jansen M, Roeder C, Hennen-Bruns D, Kremser B and Kalthoff H Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. *Cancer Res* 1998, 58:1741-1749
11. Ignjey PH and Krammer PH Death and anti-death: Tumour resistance to apoptosis. *Nature Rev Cancer* 2002, 2:277-280
12. Miyashita T and Reed JC Bcl-2 oncogene blocks chemotherapymduced apoptosis in a human leukemia cell line. *Blood* 1993, 81:151-157
13. Korsmeyer SJ Bcl-2 initiates a new category of oncogenes: regulators of cell death. *Blood* 1992, 80:879-886
14. Hager JH and Hanahan D Tumor cells utilize multiple pathways to down-modulate apoptotic. Lessons from a mouse model of islet cell carcinogenesis. *Ann N Y Acad Sci* 1999, 887:150-163
15. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Haylie AH, Sato Y and Nagata S The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. *Cell* 1991, 66:233-243
16. Suda T, Takahashi T, Golstein P and Nagata S Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. *Cell* 1993, 75:1169-1178
17. Krammer PH, Galie PR, Moller P and Debatin KM CD95 (APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. *Adv Cancer Res* 1998, 75:251-273
18. Sprick MR, Weighardt TA, Rieker E, Rauch CT, Juo P, Blenis J, Krammer PH and Walczak H FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. *Immunology* 2000, 12:599-609
19. Scaffardi C, Fulda S, Srivinasa A, Friesen C, Li F, Tomasselli KJ, Debatin KM, Krammer PH and Peter ME Two CD95 (APO-1/Fas) signaling pathways. *EMBO J* 1998, 17:1675-1687
20. Zamzami N and Kroemer G The mitochondrion in apoptosis: how Pandora’s box opens. *Nature Rev Mol Cell Biol* 2001, 2:67-71
21. Martinou JC and Green DR Breaking the mitochondrial barrier. *Nature Rev Mol Cell Biol* 2001, 2:563-67
22. Rathmell JC and Thompson CB The central effectors of cell death in the immune system. *Annu Rev Immunol* 1999, 17:781-828
23. Nagata S Apoptosis by death factor. *Cell* 1997, 88:355-365
24. Wyllie AH Apoptosis and carcinogenesis. *Eur J Cell Biol* 1997, 73:189-197
25. Nagata S and Golstein P The Fas death factor. *Science* 1995, 267:1449-1456
26. Niehaus GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR and Kratzke RA Human lung carcinomas express Fas ligand. *Cancer Res* 1997, 57:1007-1012
27. Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, Kikizoe T and Kawabe K Expression of Fas in renal cell carcinoma. *Jpn J Clin Oncol* 1997, 27:284-288
28. von Reayher U, Strater J, Kittsttein W, Gschwendt M, Krammer PH and Moller P Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. *Cancer Res* 1998, 58:526-534
29. Kornmann M, Ishiwata T, Kleefl J, Beger HG and Korc M Fas and Fas-ligand expression in human pancreatic cancer. *Ann Surg* 2000, 231:368-379
30. von Bernstorff W, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS and Eberlein TJ Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors.Impli-
cations for immune privilege and immune escape. Cancer 2002, 94:2552-2560
31. Tabuchi Y, Choi J, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Calabrias F, Andreiff M and Younes A Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997, 99:618-624.
32. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H and Ungefroren H Bcl-xL protects pan-
creatic adenocarcinoma cells against CD95- and TRAIL-recep-
tor-mediated apoptosis. Oncogene 2000, 19:5477-5486.
33. Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra M, Picha KS and Pouton CM Combination of tumor necrosis fac-
tor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 2001, 7:407-414.
34. Ashkenazi A, Pai RC, Fung S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis C, Kalthoff H, Henne-Bruns D and Kalthoff H Role of Bcl-2 family proteins in apoptosis: regulation of genes. Oncogene 1999, 18:7441-7456.
35. Van Roy T, Walter KG and Atlee RJ Cytochrome c/membrane redistribution of Bax and Bcl-xL during apoptosis. Proc Natl Acad Sci U S A 1997, 94:3668-3672.
36. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG and Green DR Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 1999, 274:2225-2233.
37. Xu ZW, Friess H, Buchler MW and Solioz M Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis in-
duced by chemotherapeutic agents. Cancer Chemother Pharmacol 2002, 49:504-510.
38. Pirovacac NC, Nüesch RP, Nagy P, Wang J, Nardin SR, Gu J, Fung B, Moossa AR, Hoffmann RM and Bouvet M Bax-induction gene ther-
apancy of pancreatic cancer. J Surg Res 2002, 106:346-351.
39. Seiki T, Ohba N, Makino R, Funatomi H and Mitamura K Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene. Anticancer Res 2001, 21:1919-1924.
40. Graber HU, Friess H, Zimmermann A, Korc M, Adler G, Schmid R and Buchler MW Bak expression and cell death occur in peri-
tumorous tissue but not in pancreatic cancer cells. J Gastroint-
test Surg 1999, 3:74-80.
41. Adachi M and Imai K The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2. Cell Death and Differentiation 2002, 9:1240-1247.
42. Basel BJ and Huang DC Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 2002, 64:851-863.
43. Ding XZ, Tong WG and Adrian TE Cyclooxygenases and lipoxygen-
ases as potential targets for treatment of pancreatic cancer. Pancreatology 2002, 2:25-31.
44. Tong WG, Ding XZ and Adrian TE The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer. Biochem Biophys Res Commun 2002, 296:942-948.
45. Turk B, Stoka V, Rozman-Pungarcic J, Corasaniti MT, Droga-Mazovec G, Oreic K and Turk V Apoptotic pathways: involvement of lyso-
osomal proteases. Biochim Biophys Acta 2002, 1551-1562.
46. Cronin V and Yuan J Proteases to die for. Genes Dev 1998, 12:1551-1570.
47. Konstantou S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGar-
try TJ, Kirschner MW, Koths K, Kwisikowski DJ and Williams LT Cas-
pase-3-generated fragment of gelsolin: effector of morpholog-
ical change in apoptosis. Science 1997, 278:294-298.
48. Takahashi A, Alnemri ES, Lazebnik YA, Fernandez-Alnemri T, Litwack G, RFL Moir, Goldman RD, Porier GG, Kaufmann SH and Earnshaw WC Cleavage of lamin A by Mch2: but not CPP32: Multiple interleukin 1-ß converting enzyme-related proteases of distinct substrate specificities are properties active in apoptotic cells. Proc Natl Acad Sci U S A 1996, 93:8385-8400.
49. Thornberry NA and Lazebnik Y Caspases: enemies within. Science 1998, 281:1312-1316.
50. Boldin M, Gorochov TM, Goltsve YV and Wallach D Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-I-and TNF receptor-induced cell death. Cell 1996, 85:803-815.
51. Li P, Nijhawan D, Budihardjo I, Vinuesa SM, Ahmad M, Alnemri ES and Wang X Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
52. Inoue M, Thome M, Meene J, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
53. Kruger A, Baumann S, Krammer PH and Kirchhoff S FLICE-inhibi-
tory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001, 21:8247-8254.
54. Goltsve YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskaia VM and Wallach D CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997, 272:1641-4.
55. Han DK, Chaudhary PM, Wright ME, Friedmann C, Trask BJ, Riedel RT, Baskin DG, Schwartz SM and Hood L MR1, a novel death-effec-
tor-domain-containing protein, interacts with caspases and Bcl-xL and initiates cell death. Proc Natl Acad Sci U S A 1997, 94:1333-8.
73. Ellemov A, Ohza T, Yachie A, Kayahara M, Kitagawa H, Fujimura T, Ninomiya I, Fushida S, Nishimura GI, Shimizu K and Miwa K Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 2001, 18:311-316

74. Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahn M, Kennedy N, Kovacsics M and Tschopp J The caspase-8 inhibitor FLIP promotes activation of NF-κB and ERK signaling pathways. Curr Biol 2000, 10:640-648

75. Bharti AC and Aggarwal BB

76. Hyer ML, Sudarshan S, Kim Y, Reed JC, Dang JY, Schwartz JY and Norris JS Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther 2002, 1:401-406

77. Kim Y, Suh N, Sporn M and Reed JC An inducible pathway for toxic activity of bcl-2 proteins suppresses cell death in mammalian cells. Exp Cell Res 2002, 277:2122-2239

78. Vernejoul F, Faure P, Benali N, Calisse D, Tiraby G, Pradayrol L, Susini T and Verroust P Expression of XIAP and c-IAP1 sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Prostate 2002, 55:242-251

79. Chakrabarty S, Roy M, Hazra B and Bhattacharya RK Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther 2002, 1:401-406

80. Wang W, Waters SJ, MacDonald JR, Roth C, Shentu S, Freeman J, Johnson R, Moritz RL, Simpson RJ and Vaux DL Induction of apoptosis by diospyrin, a plant-derived bisnaphthoquinone, and its synthetic derivatives. Cancer Lett 2002, 188:85-93

81. Vang WV, Waterhouse SJ, MacDonald JR, Roth C, Shentu S, Freeman J, Vonhoff DD and Miller AR Irofulven (6-hydroxymethylxylylene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases. Anticancer Res 2002, 22:559-564

82. Bernbaum MJ, Clem RJ and Miller LK An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol 1994, 68:2521-2528

83. Crook NE, Clem RJ and Miller LK An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993, 67:2168-2174

84. Deveraux QL and Reed JC IAP family proteins-suppressors of apoptosis. Genes Dev 1999, 13:239-252

85. Harvey AJ, Soliman H, Kaiser W and Miller LK Anti- and pro-apoptotic activities of baculovirus and Drosophila IAPs in an insect cell line. Cell Death Differ 1997, 4:733-744

86. Deveraux QL, Takahashi R, Salvesen GS and Reed JC X-linked IAP is a direct inhibitor of cell death proteases. Nature 1997, 388:300-306

87. Takahashi R, Deveraux Q, Tamam I, Wilkinson JS, Ghaemreza M, Salvesen GS and Reed JC A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998, 273:7787-7790

88. Roy N, Mahadevan MS, McLean M, Shutler G, Yarazhi G, Farahani R, Baird S, Besner-Johnson A, Lefebvre C, Kang X, Salih M, Aubry H, Tanaka K, Guan X, Iannone P, Crawford TO, de Jong PJ, Surih L, Ikeda J-E, Korneluk RG and MacKenzie A The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80:167-178

89. Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R and Zhivotovsky B Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 2002, 279:277-290

90. Hofmann HS, Simm A, Hammer A, Silber RE and Bartling B Expression of inhibitors of apoptosis (IAP) proteins in non-small cell lung cancer. J Cancer Res Clin Oncol 2002, 128:624-631

91. Zhang J, Li Y and Shen B Up-regulation of XIAP by M-CSF is associated with resistance of myeloid leukemia cells to apoptosis. Leukemia 2002, 16:2163-2165

92. McEleny KR, Watson RW, Coffey RN, ONeill AJ and Fitzpatrick JM Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002, 51:133-140

93. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-583

94. Ambrosini G, Adida C and Altieri DC A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921

95. Yamamoto T and Tanigawa N The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001, 34:207-212

96. Adida C, Berrebi D, Peuchmara M, Reyes-Mugica M and Altieri DC Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Cancer 1998, 55:882-883

97. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer Cancer Res 1998, 58:5071-5074

98. Lu CS, Altieri DC and Tanigawa N Expression of novel anti-apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998, 58:1808-1812

99. Satoh K, Kaneko K, Hirota M, Masumune A, Satoh A and Shimosegawa T Expression of inhibitor of apoptosis (IAP) family proteins-suppressors of apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001, 92:271-278

100. Verhagen AM, Eker PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-51

101. Du C, Fang M, Li Y, Li L and Wang X Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:43-51

102. Verhagen AM and Vaux DL Cell death regulation by the mammalian IAP antagonist Diablo/Smac. Apoptosis 2002, 7:163-166

103. Amt CR, Chioarean MV, Heldebrant MP, Gores GJ and Kaufmann SH Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP in situ. J Biol Chem 2002, 277:44336-44343

104. Nowell PC The clonal evolution of tumor cell populations. Science 1976, 194:23-28

105. Porter AC and Vaillancourt RR Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998, 17:1343-1352

106. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M and Beger HG Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increased expression of the EGFR, EGF and erbB2 genes and their gene products in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995, 55:2007-2011

107. Chen J and Liu TH Expression of EGF, TGF-alpha, EGFR and c-erbB2 genes and their gene products in human pancreatic carcinoma cell lines. Zentralbl Pathol 1994, 120:265-270

108. Freeman JW, Mattingly CA and Strodel WE Immunohistochemical expression of insulin-like growth factor II receptor in human pancreatic cancer. Hum Pathol 1998, 29:135-140

109. Bergmann M, Funatomi H, Yoyoyama M, Berger HG and Korc M Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995, 55:367-373

110. Ishiiwa T, Bergmann M, Kornmann L, Lopez M, Beger HG and Korc M Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas 1997, 15:165-166

111. Bergmann M, Funatomi H, Yoyoyama M, Berger HG and Korc M Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995, 55:2007-2011

112. Aris S, Mori A, Uchida S, Fujimoto K, Shimada Y and Imamura M Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999, 12:25-30

113. Kalthoff H, Roeder C, Gieseking J, Humbug I and Schmiegell W Inverse regulation of human ERBB2 and epidermal growth factor receptor genes by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1993, 90:8972-8976

114. Kalthoff H, Roeder C, Brockhaus M, Thiele HG and Schmiegell W Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. J Biol Chem 1993, 268:2762-2766

115. Schmiegell W, Roeder C, Schmieleau J, Rodeck U and Kalthoff H Tumor necrosis factor alpha induces the expression of trans-
Risk factors for pancreatic cancer are still poorly understood. Several pathways involved in the development of this cancer have been studied. The role of growth factors, such as vascular endothelial growth factor (VEGF), has been extensively investigated. VEGF is a key player in angiogenesis, the process by which new blood vessels are formed, which supports the growth of tumors. Key proteins involved in this process are VEGF receptors, which are targets for specific inhibitors.

The molecular mechanisms of VEGF receptor kinase inhibition, and its role in cell growth, transformation, apoptosis, and chemoresistance in solid tumors, have been extensively studied. The role of insulin-like growth factor (IGF) and IGF-1 receptors in the formation of VEGF receptor kinase inhibitors has been highlighted.

Angiogenesis is a complex process involving the formation of new blood vessels from pre-existing blood vessels. VEGF plays a crucial role in this process by promoting the proliferation and survival of endothelial cells. Blocking VEGF signaling can therefore have a significant impact on the growth of tumors.

Factors that regulate tumor development, maintenance, and progression of pancreatic cancer have been studied. Expression of IGF-1 receptor mRNA and its contribution to growth factor independence and increased survival of the pancreatic cancer cell line Mia PaCa-2 have been noted.

The islet tumors of pancreatic ductal adenocarcinoma are characterized by the presence of b-cells and other islet cell lineages. The role of IGF-1 receptor in the development of these tumors is significant.

The role of transforming growth factor alpha (TGFalpha) in the development of tumors has been studied. TGFalpha has been shown to contribute to growth factor independence and invasion potential in pancreatic cancer.

Overexpression of TGFalpha in human pancreatic cancer cells has been linked to resistance to tumor necrosis factor alpha (TNFalpha) treatment. TGFalpha expression during liver regeneration after partial hepatectomy and its potential interactions with transforming growth factor-alpha and hepatocyte growth factor have been extensively studied. TGFalpha inhibits the expression of nuclear factor-kappaB (NF-kappaB) in tumors.

The role of protein kinase C (PKC) in the development of pancreatic cancer has been investigated. PKC activation has been linked to the development of tumors and its potential role as a therapeutic target.

In conclusion, the molecular mechanisms of VEGF and TGFalpha in the development of pancreatic cancer are complex and involve several signaling pathways. The development of targeted therapies that block these pathways is an active area of research to improve the treatment outcomes for patients with pancreatic cancer.
155. Datta SR, Brunet A and Greenberg ME Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905-2927
156. Burgering SM and Coffey PJ Protein kinase B (c-Akt) in phosphoinositide-3-OH kinase signal transduction. Nature 1995, 376:599-602
157. Graff JR, Konieczk BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL and Neubauer BL Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000, 275:24500-24505
158. Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR and Ohnishi PS Protein kinase B regulates T lymphocyte survival, nuclear factor yB activation, and Bcl-X(L) levels in vivo. J Exp Med 2000, 191:1721-1734
159. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke PE and Parsons R Mutation of Pten/Mmc 1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999, 96:1563-1568
160. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M and Mak TW High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998, 8:1169-1178
161. Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H and Korc M Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 2002, 62:5611-5617
162. Gilmore AP, Valentinj Aj, Wang P, Ranger AM, Bundred N, O’Hare MJ, Wakeling A, Korsmeyer SJ and Streuli CH Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002, 277:27563-27570
163. Kermner P, Ankerhold R, Klocker N, Krajewski S, Reed JC and Bahr M Caspase-9: involvement in secondary death of axotomized rat retinal ganglion cells in vivo. Brain Res Mol Brain Res 2000, 85:144-150
164. Ng SSW, Tsao M-S, Nicklee T and Hedley DW Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human cancer xenografts in immunodeficient mice. Clin Cancer Res 2001, 7:3269-3275
165. Ng SSW, Tsao MS, Chow S and Hedley DW Inhibition of phosphatidylinositol 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000, 60:5451-5455
166. Ng SS, Tsao MS, Nicklee T and Hedley DW Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001, 7:3269-3275
167. Deppert W, Gohler T, Koga H and Kim E Mutant p53: “gain of function” through perturbation of nuclear structure and function? J Cell Biochem Suppl 2000, 35:115-122
168. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppe G, Kalthoff H, Ungefroren H, Lohr M and Scarpa A Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001, 439:798-802
169. Ghaneh P, Greenhalw H, Humphreys M, Wilson D, Zumstein L, Lemoine NR and Neoptolemos JP Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001, 8:199-208
170. Cascallo M, Calbo J, Gelpi JL and Mazo A Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (AdSCMV-p53) in human pancreatic cancer. Cancer Gene Ther 2000, 7:545-556

**BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp